Thera-SAbDab

OMALIZUMAB

>   Structural Summary
TherapeuticOmalizumab
TargetIGHE
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSS
Light ChainDIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIK
100% seqID Fv Structure2xa8 [Fvs: HL], 4x7s [Fvs: HL], 4x7t [Fvs: AB, HL], 5hys [Fvs: AB, CD, EF, HL], 6tcm [Fvs: HL], 6tcn [Fvs: HL], 6tco [Fvs: BA], 6tcp [Fvs: HL]
99% seqID Fv Structure5g64 [Fvs: HL, IM]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Omalizumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.14%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 31A 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 101 102 103 104 105 106 107 108 109 110 111 112 113
omalizumab E V Q L V E S G G G L V Q P G G S L R L S C A V S G Y S I T S G Y S W N W I R Q A P G K G L E W V A S I T Y D G S T N Y N P S V K G R I T I S R D D S K N T F Y L Q M N S L R A E D T A V Y Y C A R G S H Y F G H W H F A V W G Q G T L V T V S S
5g64 E V Q L V E S G G G L V Q P G G S L R L S C A V S G Y S I T S G Y S W N W I R Q A P G K G L E W V A S I T Y D G S T N Y N P S V K G R I T I S R D D S K N T F Y L Q M N S L R A E D T A V Y Y C A R G S H Y F G H W H F A V W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30A 30B 30C 30D 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
omalizumab D I Q L T Q S P S S L S A S V G D R V T I T C R A S Q S V D Y D G D S Y M N W Y Q Q K P G K A P K L L I Y A A S Y L E S G V P S R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C Q Q S H E D P Y T F G Q G T K V E I K
5g64 D I Q L T Q S P S S L S A S V G D R V T I T C R A S Q S V D Y D G D S Y M N W Y Q Q K P G K A P K L L I Y A A S Y L E S G V P S R F S G S G S G T D F T L T I S R L R P E D F A T Y Y C Q Q S H E D P Y T F G Q G T K V E I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2000
INN Year Recommended2001
Companies InvolvedDana-Farber Cancer Institute, Genentech, John Hopkins University, Novartis
Conditions ApprovedAllergic asthma, Urticaria
Conditions ActiveSeasonal allergic rhinitis, Nasal polyps, Mastocytosis, Asthma, Nephritis
Conditions DiscontinuedHypersensitivity, Peanut hypersensitivity
NotesHC IMGT 71 is V not L as in Jain paper

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]